Post-Marketing Safety of Secukinumab treatment in patients with Psoriatic Arthritis, Ankylosing Spondylitis and Psoriasis: Data from periodic safety update reports (PSUR)
Latest Information Update: 22 Nov 2018
Price :
$35 *
At a glance
- Drugs Secukinumab (Primary)
- Indications Ankylosing spondylitis; Psoriasis; Psoriatic arthritis
- Focus Adverse reactions
- 22 Nov 2018 New trial record
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting